Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2021-07-02 00:00:00 ET · period of report 2021-06-30 · accession 0000886163-21-000097 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-02 | 2021-06-30 | LGND | Korenberg Matthew E | EVP, CFO, Fin, Strategy | J - Other | $85.91 | +247 | 39.7K | +0.6% | +$21.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-06-30 | J | A | 247 | $85.91 | 39,690 | D | — | — |